Company Touts Consecutive Record Quarters for New Sales in Second Half of 2023 and Expansion in 29 New Countries

Jupiter, FL – January 24, 2024 – DoseMe, a leading provider of precision dosing software for Model Informed Precision Dosing (MIPD) and creators of DoseMeRx and DoseMe Analytics, today announces its company highlights for 2023 and outlook for 2024.

"In the post-COVID landscape, health systems are coping with stretched resources while striving to maintain high-quality patient care. Recognizing these challenges, an increasing number of institutions are adopting DoseMe analytics and using their data in a meaningful way to impact patient care,” said Paul Edwards, CEO at DoseMe. “This growing trend underpins the need for therapeutic drug monitoring and we believe the company is poised for breakthrough growth in 2024."

2023 Highlights:

Company

• DoseMe acquired by Fairlong Capital, LLC
• Paul Edwards appointed to CEO
• Dr. Sharmeen Roy, PharmD, BCPS, promoted to Chief Science and Strategy officer

• John Hardesky appointed to Chief Commercial Officer 
• Only dosing platform that is HITRUST Risk-based certified, renewed 2-year certification demonstrating the highest level of information protection assurance

   

  Science and Product

• Clinical Advisory Board Leadership - appointment of Dr. Marc Scheetz to chair, bringing a wealth of experience and background in pharmacometrics with commitment to dose optimization.
• Redefining medication efficacy standards – addition of predictive models to extend beyond traditional antibiotics, initiating a fundamental change in dosing practices, empowering clinicians to improve patient outcomes through precision medicine.

   

  Partners and Customers

• Expanded distribution network with exclusive resellers across 29 countries.

  •    Broaden genetic biomarker capabilities for precision dosing, enabling the capability in multiple hospitals resulting in significant improvements.

  •    In a series of strategic implementations, DoseMe has partnered with several distinguished healthcare institutions looking to optimize their therapeutic protocols.

  •    Advanced compliance with dosing protocols, significantly diminishing adverse events such as toxicity and acute kidney injuries (AKI) and enhancing the overall level of patient care.
  •    Integrated advanced dosing algorithms and genetic biomarker analysis into their patient care protocols, enabling more personalized treatments aligned with individual patient profiles and genetic markers.

     

    Media Awards, Articles and Global Education

• Pharma Manufacturing Editorial Board Honors DoseMe Analytics as Top Technology.

• Coverage in Bio-IT World, Express Healthcare Management, Hospital Management, Pharma Manufacturing, PharmaVoice and Technology Networks.
• Global Education and Application - webinar tailored for Australian healthcare practitioners titled "From Theory to Practice: Maximizing Aminoglycoside Efficacy with the AUC-guided TDM." This educational endeavor demonstrates our commitment to supporting healthcare systems worldwide in adopting precision dosing strategies that optimize therapy outcomes.
• Beta-lactam Monitoring Breakthroughs and Enhancements - “Cracking the PK Code: The art of precision B-lactam dosing” webinar shed light on the breakthroughs in beta-lactam therapeutic drug monitoring (TDM), including the addition of the Cefepime model.

2024 Outlook

The FDA recommendation in early 2023 to use AUC is an important and significant shift in vancomycin dosing and monitoring augmenting the mission to advance better patient outcomes. Research reports continue to include precision medicine, and dosing specifically, as a key trend in 2024 and beyond.

Among the operational plans for 2024, DoseMe will continue to build new drug models to broaden the MIPD platform, diversify the channels and add new partners that will enable the company to offer a wide range of AI-powered systems for real-time patient care. For more information, reach out to https://doseme-rx.com/contact